Glenmark Receives US FDA Approval for Fluticasone Propionate Inhalation Aerosol

Glenmark Specialty SA has received final approval from the United States Food and Drug Administration (US FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. 

The approval marks a key milestone for Glenmark as it strengthens its respiratory product portfolio in the United States market.

Bioequivalence to Reference Drug

The newly approved product has been determined by the US FDA to be bioequivalent and therapeutically equivalent to the reference listed drug, Flovent HFA. The reference product is marketed by GlaxoSmithKline and is widely used for managing respiratory conditions.

This approval allows Glenmark to market a generic version of the inhalation aerosol, offering patients a more affordable treatment alternative while maintaining the same safety and efficacy standards as the original drug.

Competitive Generic Therapy Exclusivity

Glenmark has also been granted Competitive Generic Therapy (CGT) designation for the product. As the “first approved applicant” under the relevant provisions of the Federal Food, Drug, and Cosmetic Act, the company is eligible for 180 days of CGT exclusivity upon commercialisation.

This exclusivity period provides Glenmark with a temporary competitive advantage in the market before additional generic manufacturers can launch similar versions.

Market Opportunity and Launch Timeline

The product will be distributed in the United States by Glenmark Pharmaceuticals Inc. starting in March 2026. According to IQVIA sales data for the 12-month period ending January 2026, the Flovent HFA Inhalation Aerosol 44 mcg market generated annual sales of approximately $520.1 million.

This sizable market opportunity highlights the potential commercial significance of the approval for Glenmark.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “Receiving approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation marks an important milestone in strengthening our respiratory portfolio in the U.S. The CGT designation and first approved applicant status reflect the technical expertise and dedication of our teams in bringing complex inhalation therapies to market. We remain committed to improving access to quality and affordable respiratory treatments for patients and healthcare providers.”

Conclusion

The US FDA approval for Fluticasone Propionate Inhalation Aerosol strengthens Glenmark’s presence in the respiratory therapeutics segment. With CGT exclusivity and entry into a large US market, the company is well positioned to expand its footprint in inhalation therapies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.